How does the net income from continuing operations compare to net income from discontinued operations?

Answer to the specific question

Therapeutics MD reported $545 k of net income from continuing operations for the quarter ended June 30, 2025. The release does ** not** provide any figure for net income from discontinued operations – it either wasn’t reported because there were no discontinued‑operation items for the quarter, or any such amount was immaterial and omitted from the summary. Consequently, the only disclosed figure is the positive $545 k from continuing operations; there is no disclosed counterpart for discontinued operations, implying that the continuing‑operations result is the only material net‑income line for the period.

Trading implications

- Fundamental view: A swing from a $1.05 M loss a year earlier to a $0.55 M profit in the core (continuing) business suggests improving underlying royalties and a potentially healthier cash‑flow outlook. The absence of a discontinued‑operations line suggests no material divestitures or write‑offs that could distort earnings, which is a positive signal for stability.

- Technical outlook: TXMD has been trading in a relatively tight range after the Q2 release. The positive earnings surprise may act as a catalyst for short‑term upside, especially if the stock is near a recent support level (e.g., $6.50–$6.80) and volume spikes on the news. Traders could consider a buy‑on‑breakout above the recent high (≈$7.20) with a stop just below the current support to manage risk.

- Actionable insight: With the only disclosed net‑income figure being positive, the market may price in the improvement of the core business. If you’re looking for a short‑term trade, watch for price consolidation and then a breakout; for longer‑term investors, the shift to positive continuing‑operations income adds a positive data point to the company’s valuation narrative, but monitor any future updates on discontinued‑operation items, as they could affect future earnings volatility.